We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026
20 Aug 2026 - 22 Aug 2026

Cancer Mutation Kit Launched

By Labmedica staff writers
Posted on 10 Jul 2008
A new diagnostic kit will assist clinicians to select appropriate therapy for cancer patients.

The TheraScreen K-RAS kit allows clinicians to screen patients for mutations in the K-RAS gene, which correlates with poor prognosis if patients are treated with a class of drugs called epidermal growth factor receptor (EGFR) inhibitors. More...
The gene is mutated in approximately 35-45% cases of metastatic colorectal cancer as well as a variety of other cancers. The kit will enable clinicians determine, from the outset, which patients will not respond to targeted cancer therapies such as Vectibix and Erbitux.

DxS (Manchester, UK), a personalized medicine company that develops companion diagnostics, announced the launch of its K-RAS cancer mutation detection kit in Australia. This occurred after the kit met the compliance standards of Australia's Therapeutic Goods Administration (TGA; Woden, Australia).

Dr. Stephen Little, CEO of DxS Ltd. said: "The TheraScreen kit will serve as an invaluable tool in deciding on correct treatment regimes for cancer patients and we are pleased to be able to help Australian physicians in identifying which patients will not respond to these treatments. The recent data at ASCO [American Society of Clinical Oncology] highlight the importance of verifying K-RAS status before prescribing EGFR inhibitor compounds, and the growing significance of companion diagnostics.”


Related Links:
DxS
Australia's Therapeutic Goods Administration

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Rapid Sepsis Test
SeptiCyte RAPID
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.